|
|
Dermatologists' Case
Files:
Management of Malignant and Premalignant Skin Lesions
This educational supplement to Skin & Allergy
News was supported by an educational grant from 3M Pharmaceuticals. This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News and is based on faculty interviews.
Topics
- Management of Patient With a Crusted Papule on the Nose
- A Middle-Aged Man With Psoriasis and Plantar
Warts
|
Faculty
Stephen K. Tyring, MBA, MD, PhD
Professor of Dermatology
University of Texas
Health Science Center
Houston
Robert T. Brodell, MD
Professor of Internal Medicine
Dermatology Section
Northeastern Ohio Universities College of Medicine
Rootstown
|
Back to top  |
Faculty
Disclosures
The faculty of this CME activity
disclose the following:
| Faculty Member |
|
|
|
Stephen K. Tyring,
MBA, MD, PhD |
Dr. Tyring has received grant funding, honoraria, or served on advisory boards for, and/or is a consultant to 3M Pharmaceuticals, Abbott Laboratories, Amgen, Inc., GlaxoSmithKline, Merck & Co., Inc., and Novartis Pharmaceuticals.
|
|
Robert T. Brodell,
MD
|
Dr. Brodell is a speaker for 3M Pharmaceuticals.
|
| |
| Back to top |
Target Audience
This educational activity has been
developed for dermatologists and other health care providers
involved in the diagnosis and management of skin disorders
for which immune response modifier (IRM) therapy might
be considered. |
Educational
Needs
Skin
disorders related to photodamage pose a major health issue
that has implications involving morbidity, mortality, and
health resource utilization. Various types of destructive
therapies offer the potential for high cure rates for
lesions such as actinic keratoses. However, the therapies
are not 100% effective, do not eliminate the risk of
recurrence, and can cause scarring that patients often find
unacceptable. Because photodamage to the skin arises over a
long period of time, many patients may not be good
candidates for destructive therapies.
Topical and systemic
therapies appeal to many patients seeking less invasive
alternatives to conventional approaches to treatment.
However, some of these therapies have yielded mixed results.
Recently, IRM therapy has evolved as another option for
management of actinic keratosis, superficial basal cell skin
cancer, and possibly other lesions associated with
photodamage.
In this supplement to
Skin & Allergy News, dermatology specialists share
clinical case experiences that illustrate the application of
IRM therapy in varied skin diseases.
|
| Back to top |
Learning Objectives
Upon completion of this educational activity, participants should be able to:
· idenfity
and describe therapeutic
options for skin diseases caused by
photodamage.
· describe
the results of a clinical
application of IRM therapy for a patient
with actinic keratosis.
· discuss
one clinician’s experience with an IRM
as therapy for recalcitrant plantar
warts.
|
| Back to top |
CME
Recognition
This Skin & Allergy News
supplement is recognized by
the American Academy of Dermatology (AAD) for 1 hour of AAD Category 1
Continuing Medical Education (CME) Credit and may be used toward
the AAD’s CME Award.
This activity has been planned and
implemented in accordance with the Essential Areas and
Policies of the Accreditation Council for Continuing Medical
Education (ACCME) through the joint sponsorship of the
Elsevier Office of Continuing Medical Education (EOCME) and
Skin & Allergy News. The EOCME is accredited by the
ACCME to provide continuing medical education for
physicians.
The EOCME designates this educational activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
Term of
Approval: December
2006 to November 30, 2007
Copyright
© 2006 Elsevier Inc.
|